These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Inhibitory influence of thyrotropin releasing hormone administration on growth hormone response to low doses of growth hormone-releasing hormone in normal man. Zanoboni A; Gibillini M; Cucchi MR; Zanoboni Muciaccia W; Zanussi C J Endocrinol Invest; 1988 Jun; 11(6):413-7. PubMed ID: 3145297 [TBL] [Abstract][Full Text] [Related]
63. T-lymphoblast cell lines from Laron dwarfs augment basal colony formation in response to extremely high concentrations of growth hormone. Geffner ME; Bersch N; Lippe BM; Golde DW J Clin Endocrinol Metab; 1990 Mar; 70(3):810-3. PubMed ID: 2307733 [TBL] [Abstract][Full Text] [Related]
64. Effect of psychological stress on human growth hormone response to thyrotropin-releasing hormone in normal controls. Tamai H; Esaki M; Takeno K; Matsubayashi S; Nakagawa T; Okimura MC; Walter RM; Kumagai LF Psychother Psychosom; 1986; 46(3):122-6. PubMed ID: 3114818 [TBL] [Abstract][Full Text] [Related]
65. Growth hormone releasing factor induces prolactin secretion in acromegalic patients but not in normal subjects. Losa M; Schopohl J; Müller OA; von Werder K Acta Endocrinol (Copenh); 1985 Aug; 109(4):467-73. PubMed ID: 3929513 [TBL] [Abstract][Full Text] [Related]
66. Effect of galanin on basal and stimulated secretion of prolactin, gonadotropins, thyrotropin, adrenocorticotropin and cortisol in humans. Arvat E; Gianotti L; Ramunni J; Grottoli S; Brossa PC; Bertagna A; Camanni F; Ghigo E Eur J Endocrinol; 1995 Sep; 133(3):300-4. PubMed ID: 7581945 [TBL] [Abstract][Full Text] [Related]
67. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses. Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339 [TBL] [Abstract][Full Text] [Related]
68. [Serum prolactin response to thyrotropin-releasing hormone in normal subjects and in patients with thyroid diseases (author's transl)]. Onishi T; Miyai K; Kumahara Y Nihon Naibunpi Gakkai Zasshi; 1975 Mar; 51(3):161-5. PubMed ID: 808433 [TBL] [Abstract][Full Text] [Related]
69. Absence of serum growth hormone binding protein in patients with growth hormone receptor deficiency (Laron dwarfism). Daughaday WH; Trivedi B Proc Natl Acad Sci U S A; 1987 Jul; 84(13):4636-40. PubMed ID: 3474620 [TBL] [Abstract][Full Text] [Related]
70. Effects of nutrient intake on growth, insulin-like growth factors, and their binding proteins in a Laron-type dwarf. Crosnier H; Gourmelen M; Prévot C; Rappaport R J Clin Endocrinol Metab; 1993 Jan; 76(1):248-50. PubMed ID: 7678425 [TBL] [Abstract][Full Text] [Related]
71. Value of growth hormone dynamics and somatomedin C (insulin-like growth factor I) levels in predicting the long-term benefit after transsphenoidal surgery for acromegaly. Arafah BM; Rosenzweig JL; Fenstermaker R; Salazar R; McBride CE; Selman W J Lab Clin Med; 1987 Mar; 109(3):346-54. PubMed ID: 3102658 [TBL] [Abstract][Full Text] [Related]
72. Effect of subacute cabergoline treatment on prolactin, thyroid stimulating hormone and growth hormone response to simultaneous administration of thyrotrophin-releasing hormone and growth hormone-releasing hormone in hyperprolactinaemic women. Giusti M; Lomeo A; Torre R; Sghedoni D; Mazzocchi G; Durante R; Giordano G Clin Endocrinol (Oxf); 1989 Mar; 30(3):315-21. PubMed ID: 2574083 [TBL] [Abstract][Full Text] [Related]
73. A re-evaluation of the prolactin-releasing activity of growth hormone-releasing hormone in acromegaly in vivo. Watanobe H; Tamura T Neuropeptides; 1995 Feb; 28(2):73-8. PubMed ID: 7746357 [TBL] [Abstract][Full Text] [Related]
74. The 'dawn phenomenon' in adolescents with insulin dependent diabetes mellitus: possible contribution of insulin-like growth factor binding protein-1. Cotterill AM; Daly F; Holly JM; Hughes SC; Camacho-Hübner C; Abdulla AF; Gale EA; Savage MO Clin Endocrinol (Oxf); 1995 Nov; 43(5):567-74. PubMed ID: 8548941 [TBL] [Abstract][Full Text] [Related]
75. Growth responses in a mutant dwarf rat to human growth hormone and recombinant human insulin-like growth factor I. Skottner A; Clark RG; Fryklund L; Robinson IC Endocrinology; 1989 May; 124(5):2519-26. PubMed ID: 2707163 [TBL] [Abstract][Full Text] [Related]
76. Increase in plasma growth hormone levels following thyrotropin-releasing hormone injection in children with primary hypothyroidism. Collu R; Leboeuf G; Letarte J; Ducharme JR J Clin Endocrinol Metab; 1977 Apr; 44(4):743-7. PubMed ID: 403195 [TBL] [Abstract][Full Text] [Related]
77. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Arvat E; di Vito L; Maccagno B; Broglio F; Boghen MF; Deghenghi R; Camanni F; Ghigo E Peptides; 1997; 18(6):885-91. PubMed ID: 9285939 [TBL] [Abstract][Full Text] [Related]
78. Body fat in Laron syndrome patients: effect of insulin-like growth factor I treatment. Laron Z; Klinger B Horm Res; 1993; 40(1-3):16-22. PubMed ID: 8300045 [TBL] [Abstract][Full Text] [Related]
80. Regulation of the growth hormone-insulin-like growth factor I axis in developing and adult monkeys is affected by estradiol replacement and supplementation with insulin-like growth factor I. Wilson ME J Clin Endocrinol Metab; 1998 Jun; 83(6):2018-28. PubMed ID: 9626134 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]